Crude peptide: difference between revisions
Diff·revision 4 → 5·16:31, 12 Oct 2024
Difference between revision 4 and revision 5 of Crude peptide. 3 lines changed; the page grew by 415 bytes.
| Revision 4 — 19:13, 2 Oct 2024 FmocFrancis (talk) add the note that lyophilised material tolerates excursions better than solution 1,870 bytes ±0 | Revision 5 — 16:31, 12 Oct 2024 CrudePeptidePearl (talk) attribute the stability figure to the study and its duration 2,285 bytes +415 | ||
|---|---|---|---|
| 10 | Its purity is highly variable and is largely determined by sequence. An easy 10-residue sequence may cleave at high purity; a difficult 40-residue sequence may cleave at well under half. That figure sets the cost and difficulty of everything that follows.{{r|behrendt2016}} | 10 | Its purity is highly variable and is largely determined by sequence. An easy 10-residue sequence may cleave at high purity; a difficult 40-residue sequence may cleave at well under half. That figure sets the cost and difficulty of everything that follows.{{r|behrendt2016}} |
| 11 | 11 | ||
| + | 12 | Crude peptide is sold as such in some markets, principally where the purchaser intends to purify it. Material described only as "crude" is not a defective product; it is an intermediate, and describing it accurately is what distinguishes it from a purified one.{{r|usp1503}} | |
| + | 13 | ||
| 12 | == What is in it == | 14 | == What is in it == |
| 13 | The dominant impurities are sequence-related: deletion sequences missing one or more residues where a coupling failed, truncated sequences where a chain was capped, and any peptide bearing residual protecting groups where cleavage was incomplete.{{r|behrendt2016,merrifield1963}} | 15 | The dominant impurities are sequence-related: deletion sequences missing one or more residues where a coupling failed, truncated sequences where a chain was capped, and any peptide bearing residual protecting groups where cleavage was incomplete.{{r|behrendt2016,merrifield1963}} |
| ⋮ | ⋮ | ||
| 18 | {{reflist}} | 20 | {{reflist}} |
| 19 | <ref name="behrendt2016">Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." ''Journal of Peptide Science'' 22(1):4–27 (2016). PMID 26785684.</ref> | 21 | <ref name="behrendt2016">Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." ''Journal of Peptide Science'' 22(1):4–27 (2016). PMID 26785684.</ref> |
| + | 22 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | |
| 20 | <ref name="merrifield1963">Merrifield RB. "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide." ''Journal of the American Chemical Society'' 85(14):2149–2154 (1963). DOI:10.1021/ja00897a025.</ref> | 23 | <ref name="merrifield1963">Merrifield RB. "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide." ''Journal of the American Chemical Society'' 85(14):2149–2154 (1963). DOI:10.1021/ja00897a025.</ref> |
| 21 | 24 |